Small Door Veterinary Expands NYC Footprint With Park Slope Location
Small Door Inc., a tech-enabled, membership-first veterinary care provider operating under the brand Small Door Veterinary, today announced the opening of its sixth New York City location with a state-of-the-art practice at 435 9th Street in the Park Slope neighborhood of Brooklyn. This marks Small Door’s second Brooklyn location, joining its Williamsburg practice as part of its continued expansion.
VetriScience® and Senior Dog Veterinary Society Partner to Better Support Pets in Their Golden Years
VetriScience, a company focused on veterinary nutritional supplements and backed by over 40 years of veterinarian-led science and clinical testing, today announced a strategic partnership with the Senior Dog Veterinary Society (SDVS), a leader in continuing education and certification focused on senior canine wellness.
UC Davis Welcomes 57 New House Officers
The UC Davis School of Veterinary Medicine (SVM) has welcomed 57 new house officers to its advanced clinical training programs this year, including 41 residents, 8 fellows, and 8 interns. With 144 total house officers currently in training, the UC Davis House Officer Program remains the largest of its kind in the United States. The program spans approximately 40 specialties, offering one- to four-year opportunities in areas such as oncology, equine surgery, internal medicine, and anesthesiology.
"We’re Not Just Tired — We’re Breaking": UC Davis Vet Techs Protest Over Staffing Shortages and Patient Safety
Veterinary technicians at UC Davis protested on July 29 over critical staffing shortages and wage disparities, warning that patient care is at risk. Read the full story.
FDA Gives Conditional Green Light to First-Ever Drug for Subclinical HCM in Cats: Felycin®-CA1 Now Available to Veterinarians
Felycin®-CA1 becomes the first and only FDA-conditionally approved drug for managing subclinical hypertrophic cardiomyopathy (HCM) in cats. Learn how it’s changing feline cardiac care.
Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.